Raymond James Financial Services Advisors Inc. Trims Stake in Repligen Co. (NASDAQ:RGEN)

Raymond James Financial Services Advisors Inc. reduced its position in shares of Repligen Co. (NASDAQ:RGEN) by 53.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,773 shares of the biotechnology company’s stock after selling 3,207 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Repligen were worth $801,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Samson Rock Capital LLP purchased a new position in Repligen during the 3rd quarter worth $1,932,000. Goldman Sachs Group Inc. boosted its position in Repligen by 3.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 342,357 shares of the biotechnology company’s stock valued at $68,341,000 after acquiring an additional 12,846 shares in the last quarter. AXA S.A. boosted its position in Repligen by 54.9% during the 2nd quarter. AXA S.A. now owns 40,900 shares of the biotechnology company’s stock valued at $8,164,000 after acquiring an additional 14,500 shares in the last quarter. Ergoteles LLC bought a new stake in Repligen during the 2nd quarter valued at $311,000. Finally, AlphaCrest Capital Management LLC boosted its position in Repligen by 101.8% during the 2nd quarter. AlphaCrest Capital Management LLC now owns 4,217 shares of the biotechnology company’s stock valued at $842,000 after acquiring an additional 2,127 shares in the last quarter. Institutional investors own 84.96% of the company’s stock.

Several analysts have issued reports on RGEN shares. Craig Hallum increased their target price on Repligen from $258.00 to $368.00 and gave the company a “buy” rating in a research report on Monday, September 27th. BNP Paribas started coverage on Repligen in a research report on Thursday, October 14th. They set an “outperform” rating and a $330.00 target price on the stock. KeyCorp increased their target price on Repligen from $255.00 to $335.00 and gave the company an “overweight” rating in a research report on Friday, September 17th. Zacks Investment Research raised Repligen from a “hold” rating to a “strong-buy” rating and set a $285.00 price objective for the company in a research report on Tuesday, December 7th. Finally, Exane BNP Paribas began coverage on Repligen in a research report on Thursday, October 14th. They issued an “outperform” rating and a $330.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $312.88.

In other Repligen news, CEO Anthony Hunt sold 17,355 shares of Repligen stock in a transaction dated Thursday, November 18th. The stock was sold at an average price of $276.85, for a total transaction of $4,804,731.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karen A. Dawes sold 2,400 shares of Repligen stock in a transaction dated Tuesday, November 2nd. The shares were sold at an average price of $303.94, for a total value of $729,456.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,400 shares of company stock valued at $6,296,277. 1.20% of the stock is currently owned by insiders.

Shares of RGEN opened at $193.26 on Friday. The stock has a 50-day moving average of $256.43 and a two-hundred day moving average of $258.60. Repligen Co. has a one year low of $162.29 and a one year high of $327.32. The stock has a market cap of $10.69 billion, a P/E ratio of 92.03 and a beta of 0.78.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, October 28th. The biotechnology company reported $0.78 EPS for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. Repligen had a return on equity of 9.81% and a net margin of 20.06%. The company had revenue of $178.22 million during the quarter, compared to analysts’ expectations of $163.97 million. During the same quarter in the previous year, the firm posted $0.40 EPS. The firm’s revenue was up 89.5% compared to the same quarter last year. As a group, equities research analysts predict that Repligen Co. will post 2.9 EPS for the current fiscal year.

About Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Story: What are the risks of holding treasury bonds?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.